Ole Maaløes Vej 3
About OrphazymeOrphazyme ApS is a Danish biotech company that develops paradigm-changing medicines for the treatment of protein misfolding diseases with well-characterised mechanisms of disease. The lead programme is in development as a treatment for the lysosomal storage disease Niemann-Pick disease type C. This is one of a family ~50 debilitating genetic disorders that often affect children, most of whom are currently untreatable.
CEO: Anders Hinsby
Please click here for Orphazyme job opportunities.
Tweets by Orphazyme
57 articles with Orphazyme
Orphazyme A/S, held its Annual General Meeting, at which the Annual General Meeting.
Orphazyme A/S, hereby provides notice to holders of American Depositary Shares evidenced by American Depositary Receipts representing deposited common shares of the Company regarding termination of the Deposit Agreement dated September 28, 2020 among the Company, The Bank of New York Mellon, as depositary, and Owners and ADR Holders.
Orphazyme A/S, reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
Orphazyme A/S, announces the notice to convene the Company’s Annual General Meeting to be held.
Following completion of the Sale of Assets to KemPharm, Orphazyme will no longer have any material ongoing operational business activities and KemPharm will retain all of Orphazyme’s remaining Danish employees, to continue the early access programs with arimoclomol, and to continue to pursue the potential approval of arimoclomol as a treatment option for NPC.
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, announces that an in-court meeting was held where the restructuring proposal as published by the Company through company announcement no. 26/2022 on May 18, 2022, was approved by the Company’s creditors and affirmed by the Danish Maritime and Commercial High Court in accordance with sections 13 d and 13 e of the Danish Insolvency Act.
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, has previously announced its entry into an agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities and submission of the restructuring proposal to the Danish Maritime and Commercial High Court and the Company’s known creditors.
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
KemPharm, Inc. announced a definitive agreement with Orphazyme A/S to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier being developed as a treatment for Niemann-Pick disease type C.
Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company's assets and operations.
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C, announces that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, announces that following the Company’s voluntary delisting of the Company’s American Depositary Shares representing its ordinary shares from Nasdaq Global Select Market has become effective on March 31, 2022.
Orphazyme A/S announces an update to the Company’s Financial Calendar for 2022, following that the Danish Business Authority upon request from the Company has approved to extend the deadline for the Company’s filing of its annual report for the financial year ended December 31, 2021, following the in-court restructuring proceedings of the Company (please see company announcements no. 10/2022 and 11/2022).
Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C
Orphazyme A/S announces that, following the receipt of the negative Trend Vote by the Committee for Medicinal Products for Human Use (CHMP) as announced on February 23, 2022 (please see company announcement no. 07/2022), the Company has decided to withdraw its European Marketing Authorisation Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease Type C.
Orphazyme A/S, today initiated the delisting and filed a Form 25 with the Securities and Exchange Commission (“SEC”). The delisting is expected to become effective on March 31, 2022.
Orphazyme A/S announces that following the Company’s filing of a petition for an in-court restructuring (in Danish rekonstruktion) of Orphazyme on March 10, 2022, the Danish Maritime and Commercial High Court (the “Court”) has commenced the restructuring proceedings of the Company on March 11, 2022 at 7:00 am (CET).
The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.
Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S, a late-stage biopharmaceutical company, announced an update to the Financial Calendar for 2022.
Orphazyme A/S, a late-stage biopharmaceutical company, announces that CFO Anders Vadsholt will be appointed CEO of Orphazyme effective as of March 1, 2022 and thereby replacing Christophe Bourdon as announced in company announcement no. 3/2022 of January 31, 2022.
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).